Should Quinolones Come First in Helicobacter Pylori Therapy?

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2011 Jun 23

PMID 21694812

Citations 28

Authors

Marco Berning

Susanne Krasz

Stephan Miehlke

Affiliations

Soon will be listed here.

Abstract

New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been successfully introduced into the treatment of Helicobacter pylori infection. Based on a large body of evidence, current guidelines recommend the use of levofloxacin- or moxifloxacin-containing proton-pump inhibitor (PPI) triple therapies in second-line or rescue treatment of H. pylori infection. The efficacy of standard PPI triple therapies has substantially declined during the last decade, mainly due to increasing resistance against the key antibiotics clarithromycin and metronidazole. Therefore, alternative strategies for first-line therapy of H. pylori infection have been evaluated in a considerable number of clinical trials including sequential regimens, nonbismuth quadruple regimens, and quinolone-containing PPI triple therapy regimens. The aim of this paper is to summarize the current body of evidence of levofloxacin- and moxifloxacin-containing regimens in first-line treatment of H. pylori infection, and to discuss the risks and benefits of these strategies in the light of increasing resistance of H. pylori to quinolones.

Citing Articles

Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.

Millanao A, Mora A, Villagra N, Bucarey S, Hidalgo A Molecules. 2021; 26(23).

PMID: 34885734 PMC: 8658791. DOI: 10.3390/molecules26237153.

Revisiting Therapeutic Strategies for Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies.

Cardos I, Zaha D, Sindhu R, Cavalu S Molecules. 2021; 26(19).

PMID: 34641620 PMC: 8512130. DOI: 10.3390/molecules26196078.

A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with infection.

Mokhtare M, Nikkhah M, Behnam B, Agah S, Bahardoust M, Masoodi M Indian J Pharmacol. 2020; 52(4):266-271.

PMID: 33078727 PMC: 7722916. DOI: 10.4103/ijp.IJP_719_19.

Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?.

Etik D, Sezer S, Suna N, Oztas E, Kilic Z Turk J Gastroenterol. 2019; 30(8):667-672.

PMID: 31258136 PMC: 6699571. DOI: 10.5152/tjg.2019.18793.

Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients.

Haj Yahia S, Ben Zvi I, Livneh A Rheumatol Int. 2017; 38(1):141-147.

PMID: 28975396 DOI: 10.1007/s00296-017-3823-1.

References

Chisholm S, Owen R . Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. J Med Microbiol. 2009; 58(Pt 10):1322-1328. DOI: 10.1099/jmm.0.011270-0. View

Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S . Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007; 25(12):1429-34. DOI: 10.1111/j.1365-2036.2007.03331.x. View

Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G . Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006; 11(4):237-42. DOI: 10.1111/j.1523-5378.2006.00407.x. View

Glocker E, Stueger H, Kist M . Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother. 2006; 51(1):346-9. PMC: 1797685. DOI: 10.1128/AAC.00614-06. View

Bauernfeind A . Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1998; 40(5):639-51. DOI: 10.1093/jac/40.5.639. View

Iacopini F, Crispino P, Paoluzi O, Consolazio A, Pica R, Rivera M . One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis. 2005; 37(8):571-6. DOI: 10.1016/j.dld.2005.03.007. View

Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D . Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007; 39(11):1001-5. DOI: 10.1016/j.dld.2007.06.016. View

McCusker M, Harris A, Perencevich E, Roghmann M . Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003; 9(6):730-3. PMC: 3000134. DOI: 10.3201/eid0906.020385. View

Nista E, Candelli M, Zocco M, Cremonini F, Ojetti V, Finizio R . Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol. 2006; 101(9):1985-90. DOI: 10.1111/j.1572-0241.2006.00716.x. View

10.

Romano M, Iovene M, Russo M, Rocco A, Salerno R, Cozzolino D . Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol. 2008; 61(10):1112-5. DOI: 10.1136/jcp.2008.060392. View

11.

Kilic Z, Koksal A, Cakal B, Nadir I, Ozin Y, Kuran S . Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci. 2008; 53(12):3133-7. DOI: 10.1007/s10620-008-0285-z. View

12.

Wong W, Gu Q, Lam S, Fung F, Lai K, Hu W . Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17(4):553-60. DOI: 10.1046/j.1365-2036.2003.01459.x. View

13.

Hung K, Sheu B, Chang W, Wu H, Liu C, Wu J . Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009; 14(1):61-5. DOI: 10.1111/j.1523-5378.2009.00655.x. View

14.

Heep M, Kist M, Strobel S, Beck D, Lehn N . Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis. 2000; 19(7):538-41. DOI: 10.1007/s100960000288. View

15.

Antos D, Schneider-Brachert W, Bastlein E, Hanel C, Haferland C, Buchner M . 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006; 11(1):39-45. DOI: 10.1111/j.0083-8703.2006.00375.x. View

16.

Bogaerts P, Berhin C, Nizet H, Glupczynski Y . Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006; 11(5):441-5. DOI: 10.1111/j.1523-5378.2006.00436.x. View

17.

Liou J, Lin J, Chang C, Chen M, Cheng T, Lee Y . Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010; 59(5):572-8. DOI: 10.1136/gut.2009.198309. View

18.

Cheon J, Kim N, Lee D, Kim J, Kim J, Jung H . Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter. 2006; 11(1):46-51. DOI: 10.1111/j.0083-8703.2006.00371.x. View

19.

Fennerty M, Lieberman D, Vakil N, Magaret N, Faigel D, Helfand M . Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med. 1999; 159(14):1562-6. DOI: 10.1001/archinte.159.14.1562. View

20.

Ahuja V, Dhar A, Bal C, Sharma M . Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther. 1998; 12(6):551-5. DOI: 10.1046/j.1365-2036.1998.00338.x. View